ICU sedation, delirium & recovery
Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial
Primary resultResult — go to the resultDifference 0 95% CI −6.5% to 6.4%Authors' conclusion
Remimazolam besylate could be non-inferior to propofol for achieving successful short-term light sedation in the ICU.
Study context
- Population
- Mechanically ventilated ICU patients needing light sedation (Richmond Agitation-Sedation Scale (RASS) −2 to + 1)randomized equally
- Participants
- 164 participants
- Comparison
- Remimazolam besylate vs propofol for short-term light sedation
- Primary endpoint
- Successful sedation: no rescue sedative during study drug infusion while maintaining RASS −2 to + 1 for ≥70% of total infusion time
Methodological detailsmulticentre, single-blind, non-inferiority
- Multicentre
- Single-blind
- Non-inferiority
Primary result
As reported in the abstract
Difference
0
95% CI −6.5% to 6.4%
P = 0.497
By group
Remimazolam vs Propofol
difference 0 (95% CI −6.5% to 6.4%); P = 0.497
Further findings
Infusion duration
P = 0.534
Average maintaining dose
Mean
| Outcome | Remimazolam | Propofol | P value |
|---|---|---|---|
| Mean percentage of time with target RASS scoresNo significant difference | 88.6% (95% CI 84.2%–92.9%) | 89.4% (95% CI 85.0%–93.8%) | P = 0.543 |
Original publication
Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial. Intensive Care Med. Published 31 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →